Optimization of Ciprofloxacin Hydrochloride Spray-Dried Microparticles for Pulmonary Delivery Using Design of Experiments

Ciprofloxacin is a broad-spectrum antibiotic for treatment of pulmonary diseases such as chronic obstructive pulmonary disease and cystic fibrosis. The purpose of this work was to rationally study the spray drying of ciprofloxacin in order to identify the formulation and operating conditions that lead to a product with aerodynamic properties appropriate for dry powder inhalation. A 24 − 1 fractional factorial design was applied to investigate the effect of selected variables (i.e., ciprofloxacin hydrochloride (CIP) concentration, drying air inlet temperature, feed flow rate, and atomization air flow rate) on several product and process parameters (i.e., particle size, aerodynamic diameter, moisture content, densities, porosity, powder flowability, outlet temperature, and process yield) and to determine an optimal condition. The studied factors had a significant effect on the evaluated responses (higher p value 0.0017), except for the moisture content (p value > 0.05). The optimal formulation and operating conditions were as follows: CIP concentration 10 mg/mL, drying air inlet temperature 110°C, feed volumetric flow rate 3.0 mL/min, and atomization air volumetric flow rate 473 L/h. The product obtained under this set had a particle size that guarantees access to the lung, a moisture content acceptable for dry powder inhalation, fair flowability, and high process yield. The PDRX and SEM analysis of the optimal product showed a crystalline structure and round and dimpled particles. Moreover, the product was obtained by a simple and green spray drying method.

[1]  P. J. Atkins Dry powder inhalers: an overview. , 2005, Respiratory care.

[2]  V. Bucalá,et al.  New alginic acid-atenolol microparticles for inhalatory drug targeting. , 2014, Materials science & engineering. C, Materials for biological applications.

[3]  Juliana Piña,et al.  Modelling of the spray drying process for particle design , 2018 .

[4]  Y. Yeo,et al.  Mannitol‐Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model , 2011, Biotechnology and bioengineering.

[5]  R. Löbenberg,et al.  Effervescent dry powder for respiratory drug delivery. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Virgil A Marple,et al.  Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[7]  I. Vural,et al.  Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients , 2017, Drug development and industrial pharmacy.

[8]  A. Healy,et al.  Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid. , 2013, Molecular pharmaceutics.

[9]  Alejandro Sosnik,et al.  Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. , 2015, Advances in colloid and interface science.

[10]  M Hoppentocht,et al.  Technological and practical challenges of dry powder inhalers and formulations. , 2014, Advanced drug delivery reviews.

[11]  H. Chan,et al.  Controlled release antibiotics for dry powder lung delivery , 2009, Drug development and industrial pharmacy.

[12]  John R. Nimmo,et al.  POROSITY AND PORE-SIZE DISTRIBUTION , 2013 .

[13]  M. Ricci,et al.  The influence of feedstock and process variables on the encapsulation of drug suspensions by spray-drying in fast drying regime: the case of novel antitubercular drug–palladium complex containing polymeric microparticles. , 2014, Journal of pharmaceutical sciences.

[14]  R. Tan,et al.  A novel inhaled multi-pronged attack against respiratory bacteria. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  H. Linden,et al.  The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. , 2002, International journal of pharmaceutics.

[16]  Hwa-Chi Wang,et al.  Particle Density Correction for the Aerodynamic Particle Sizer , 1987 .

[17]  R. Ambrus,et al.  Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach , 2016, Drug design, development and therapy.

[18]  H. Chan,et al.  Cospray dried antibiotics for dry powder lung delivery. , 2008, Journal of pharmaceutical sciences.

[19]  J. Emerson,et al.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis , 2002, Pediatric pulmonology.

[20]  D. Cipolla Will pulmonary drug delivery for systemic application ever fulfill its rich promise? , 2016, Expert opinion on drug delivery.

[21]  G. Sotgiu,et al.  Preventing and controlling tuberculosis among refugees in Europe: more is needed , 2016, European Respiratory Journal.

[22]  Paul T Anastas,et al.  Origins, current status, and future challenges of green chemistry. , 2002, Accounts of chemical research.

[23]  P. Seville,et al.  Spray-dried powders for pulmonary drug delivery. , 2007, Critical reviews in therapeutic drug carrier systems.

[24]  I. Kioumis,et al.  Pharmacokinetics of Ciprofloxacin and Its Penetration into Bronchial Secretions of Mechanically Ventilated Patients with Chronic Obstructive Pulmonary Disease , 2011, Antimicrobial Agents and Chemotherapy.

[25]  Sanyog Jain,et al.  Targeted Drug Delivery : Concepts and Design , 2015, Advances in Delivery Science and Technology.

[26]  S. Sethi,et al.  Optimizing antibiotic selection in treating COPD exacerbations , 2008, International journal of chronic obstructive pulmonary disease.

[27]  U. Elofsson,et al.  Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. , 2003, Journal of pharmaceutical sciences.

[28]  V. Bucalá,et al.  Influence of spray-drying operating conditions on Rhamnus purshiana (Cáscara sagrada) extract powder physical properties , 2011 .

[29]  J. Elborn,et al.  LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/offvsplacebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB) , 2016 .

[30]  Filipe Gaspar,et al.  Fundamental analysis of particle formation in spray drying , 2013 .

[31]  H. Goicoechea,et al.  Experimental design and multiple response optimization. Using the desirability function in analytical methods development. , 2014, Talanta.

[32]  Q. Yin,et al.  The crystal habit of ciprofloxacin hydrochloride monohydrate crystal , 2005 .

[33]  H. Chan,et al.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  R. Kubin,et al.  Oral Ciprofloxacin in the Treatment of Pseudomonas Exacerbations of Paediatric Cystic Fibrosis: Clinical Efficacy and Safety Evaluation Using Magnetic Resonance Image Scanning , 1998, The Journal of international medical research.

[35]  J. Elborn,et al.  Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[36]  W Press,et al.  Crystalline solids. , 1980, Science.

[37]  V. Bucalá,et al.  Formulation and Characterization of Polysaccharide Microparticles for Pulmonary Delivery of Sodium Cromoglycate , 2016, AAPS PharmSciTech.

[38]  K. Gnanaprakash,et al.  Dry Powder Inhalers - An Overview , 2016 .

[39]  Stefan Willmann,et al.  Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study , 2013, Clinical Drug Investigation.

[40]  K. Amighi,et al.  Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. , 2013, International journal of pharmaceutics.

[41]  P. Kan,et al.  Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity. , 2013, International journal of pharmaceutics.

[42]  R. Hartmann,et al.  Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections , 2015, Pharmaceutical Research.

[43]  T. Murphy,et al.  Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review , 2001, Clinical Microbiology Reviews.

[44]  Ian D Fisk,et al.  Optimization of Spray-Drying Process Conditions for the Production of Maximally Viable Microencapsulated L. acidophilus NCIMB 701748 , 2013 .

[45]  M. Niederman,et al.  Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. , 1998, Chest.

[46]  K. Abnous,et al.  Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients. , 2014, International journal of pharmaceutics.

[47]  Jianfeng Chen,et al.  Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI) , 2009 .

[48]  Ayhan Topuz,et al.  Spray-drying of fruit and vegetable juices: Effect of drying conditions on the product yield and physical properties , 2017 .

[49]  Reinhard Vehring,et al.  Pharmaceutical Particle Engineering via Spray Drying , 2007, Pharmaceutical Research.

[50]  P. Bukovec,et al.  Comparison of the thermal stability of ciprofloxacin and its compounds , 1996 .

[51]  T. Murphy,et al.  Bacterial infection in chronic obstructive pulmonary disease. , 1992, The American review of respiratory disease.